This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Telik's Antitumor Drug Shows Positive Results

Biotech firm Telik (TELK) said its new chemotherapeutic drug showed evidence of clinical benefit in several cancer types during Phase I tests.

The California-based company said its new drug, TLK286, a small antitumor drug with a "smart" action mechanism triggered by an enzyme present in many human cancers, was well-tolerated and indications of antitumor activity were observed.

In a press release, Telik said, "Most chemotherapeutic drugs cause toxicities from which patients must recover before subsequent doses. TLK286 administration has been associated with generally mild toxicities, most of which has been classified as Grade 1 or 2 in severity."

In the Phase I tests, 37 patients were treated with escalating doses of TLK286 on both weekly and once-every-three-week schedules for extended periods "without evidence of cumulative toxicity."

Shares of Telik closed at $11.22 Friday before the news release.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
TELK $2.75 -8.33%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs